CVRx Posts 20% Revenue Growth in Q1 2026, Launches Key Clinical Trial
Event summary
- Q1 2026 revenue expected to reach $14.7M–$14.8M, up 20% YoY from $12.3M in Q1 2025.
- 30-day Medicare Advantage prior authorization approval rate improved to 50% in early 2026, up from 44% in 2025.
- First site activated in BENEFIT-HF trial, with enrollment set to begin in Q2 2026.
- Gross margin expanded to 87% in Q1 2026, up from 84% in Q1 2025.
- U.S. active implanting centers grew to 257 as of March 31, 2026, up from 252 at year-end 2025.
The big picture
CVRx’s strong Q1 2026 performance reflects the early benefits of the Category I CPT Code, which streamlined reimbursement for its Barostim device. The launch of the BENEFIT-HF trial positions the company to potentially triple its addressable market, though execution risks remain. The cardiovascular neuromodulation space is increasingly competitive, with reimbursement dynamics and clinical trial outcomes serving as key differentiators.
What we're watching
- Trial Expansion
- Whether the BENEFIT-HF trial can successfully expand Barostim’s patient population threefold.
- Reimbursement Momentum
- How sustained improvement in Medicare Advantage approval rates will impact adoption.
- Operational Scaling
- The pace at which CVRx can maintain 20% revenue growth amid rising operating expenses.
Our editorial coverage: